Enbrel Maxing Out: Wyeth Sees Sales At Top End Of Forecast
This article was originally published in The Pink Sheet Daily
Executive Summary
Wyeth is "more confident than ever" that Enbrel will be "category leader" for TNF inhibitors, firm says. Enbrel on track for about $1.8 bil. in revenues this year.
You may also be interested in...
Amgen Polishes Enbrel Label
The TNF-inhibitor adds first-in-class claim for “major clinical response” in rheumatoid arthritis and gets approval for new once-weekly prefilled syringe. Five-year radiographic data also added to the label.
Amgen Polishes Enbrel Label
The TNF-inhibitor adds first-in-class claim for “major clinical response” in rheumatoid arthritis and gets approval for new once-weekly prefilled syringe. Five-year radiographic data also added to the label.
Abbott Predicts Humira Will Become $1 Bil. Product In 2005
Adalimumab continues to eat away at Enbrel’s share of the self-injectable rheumatoid arthritis market, accounting for 27% of new prescriptions, up 2.5 points from December, Abbott says.